Gabapentin, sold under the brand name Neurontin among others, is an anticonvulsant medication primarily used to treat partial seizures and neuropathic pain.[4][7] It is commonly used medication for the treatment of neuropathic pain caused by diabetic neuropathy, postherpetic neuralgia, and central pain.[8] It is moderately effective: about 30–40% of those given gabapentin for diabetic neuropathy or postherpetic neuralgia have a meaningful benefit.[9]
Gabapentin was first approved for use in 1993.[13] It has been available as a generic medication in the United States since 2004.[14] In 2020, it was the tenth most commonly prescribed medication in the United States, with more than 49million prescriptions.[15][16] During the 1990s, Parke-Davis, a subsidiary of Pfizer, used a number of illegal techniques to encourage physicians in the United States to prescribe gabapentin for unapproved uses.[17] They have paid out millions of dollars to settle lawsuits regarding these activities.[18]
Medical uses
Gabapentin is recommended for use in focal seizures and neuropathic pain.[4][7] Gabapentin is widely prescribed off-label in the US and UK,[19][20] for example, for the treatment of non-neuropathic pain,[19]anxiety disorders and bipolar disorder.[21] There is concern regarding gabapentin's off-label use due to the lack of strong scientific evidence for its efficacy in multiple conditions and its proven side effects.[22][23]
Gabapentin is recommended as a first-line treatment for chronic neuropathic pain by various medical authorities.[7][8][26][27] This is a general recommendation applicable to all neuropathic pain syndromes except for trigeminal neuralgia, where it may be used as a second- or third-line agent.[8][27]
In regard to the specific diagnoses, a systematic review has found evidence for gabapentin to provide pain relief for some patients with postherpetic neuralgia and diabetic neuropathy.[9] Gabapentin is approved for the former indication in the US.[4] In addition to these two neuropathies, European Federation of Neurological Societies guideline notes gabapentin effectiveness for central pain.[8] A combination of gabapentin with an opioid or nortriptyline may work better than either drug alone.[8][27]
Gabapentin shows substantial benefit (at least 50% pain relief or a patient global impression of change (PGIC) "very much improved") for neuropathic pain (postherpetic neuralgia or peripheral diabetic neuropathy) in 30–40% of subjects treated as compared to those treated with placebo.[9]
Evidence finds little or no benefit and significant risk in those with chronic low back pain or sciatica.[28][29] Gabapentin is not effective in HIV-associated sensory neuropathy[30] and neuropathic pain due to cancer.[31]
Anxiety
There is a small amount of research on the use of gabapentin for the treatment of anxiety disorders.[32][33]
In a controlled trial of breast cancer survivors with anxiety,[33] and in a trial for social phobia,[32] gabapentin significantly reduced anxiety levels.
Gabapentin is effective in treating sleep disorders such as insomnia and restless legs syndrome that are the result of an underlying illness, but comes with some risk of discontinuation and withdrawal symptoms after prolonged use at higher doses.[34]
Gabapentin enhances slow-wave sleep in patients with primary insomnia. It also improves sleep quality by elevating sleep efficiency and decreasing spontaneous arousal.[35]
Drug dependence
Gabapentin is moderately effective in reducing the symptoms of alcohol withdrawal and associated craving.[36][37][38] The evidence in favor of gabapentin is weak in the treatment of alcoholism: it does not contribute to the achievement of abstinence, and the data on the relapse of heavy drinking and percent of days abstinent do not robustly favor gabapentin; it only decreases the percent days of heavy drinking.[39]
Gabapentin is ineffective in cocaine dependence and methamphetamine use,[40] and it does not increase the rate of smoking cessation.[41] Gabapentin does not significantly reduce the symptoms of opiate withdrawal.[40] There is insufficient evidence for its use in cannabis dependence.[42]
Other
Gabapentin is recommended as a first-line treatment of the acquired pendular nystagmus, torsional nystagmus, and infantile nystagmus; however, it does not work in periodic alternating nystagmus.[43][44][45]
Gabapentin decreases the frequency of hot flashes in both menopausal women and patients with breast cancer. However, antidepressants have similar efficacy, and treatment with estrogen more effectively prevents hot flashes.[46]
Gabapentin should be used carefully and at lower doses in people with kidney problems due to possible accumulation and toxicity. It is unclear if it is safe during pregnancy or breastfeeding.[4]
Urinary incontinence associated with gabapentin was rarely reported in the literature. Noteworthy, this side effect was already verified by rechallenge.[64]
Suicide
The gabapentin label contains a warning of an increased risk of suicidal thoughts and behaviors.[4] According to an insurance claims database study, gabapentin use is associated with about 40% increased risk of suicide, suicide attempt and violent death as compared with a reference anticonvulsant drug topiramate. The risk is increased for both bipolar disorder and epilepsy patients.[65] Another study has shown an approximately doubled rate of suicide attempts and self-harm in patients with bipolar disorder who are taking gabapentin versus those taking lithium.[66]
A large Swedish study suggests that gabapentinoids are associated with an increased risk of suicidal behaviour, unintentional overdoses, head/body injuries, and road traffic incidents and offences.[67]
Respiratory depression
Serious breathing suppression, potentially fatal, may occur when gabapentin is taken together with opioids, benzodiazepines, or other depressants, or by people with underlying lung problems such as COPD.[68][69] Gabapentin and opioids are commonly prescribed or abused together, and research indicates that the breathing suppression they cause is additive. For example, gabapentin use before joint replacement or laparoscopic surgery increased the risk of respiratory depression by 30–60%.[68]
Withdrawal and dependence
Withdrawal symptoms typically occur 1–2 days after abruptly stopping gabapentin (almost unambiguously due to extended use and during a very short-term rebound) phenomenon, similar to, albeit less intense than virtually all benzodiazepines.[70] Agitation, confusion and disorientation are the most frequently reported, followed by gastrointestinal complaints and sweating, and more rare tremor, tachycardia, hypertension and insomnia.[70] In some cases, users experience withdrawal seizures after chronic or semi-chronic use in the absence of periodic cycles or breaks during repeating and consecutive use.[71] All these symptoms subside when gabapentin is re-instated[70] or tapered off gradually at an appropriate rate.[citation needed]
On its own, gabapentin appears to not have a substantial addictive power. In human and animal experiments, it shows limited to no rewarding effects. The vast majority of people abusing gabapentin are current or former abusers of opioids or sedatives.[71] In these persons, gabapentin can boost the opioid "high" as well as decrease commonly experienced opioid-withdrawal symptoms such as anxiety.[72]
Overdose
Through excessive ingestion, accidental or otherwise, persons may experience overdose symptoms including drowsiness, sedation, blurred vision, slurred speech, somnolence, uncontrollable jerking motions, and anxiety. A very high amount taken is associated with breathing suppression, coma, and possibly death, particularly if combined with alcohol or opioids.[71][73]
Pharmacology
Pharmacodynamics
Gabapentin is a ligand of the α2δ calcium channel subunit.[74][75] α2δ is an auxiliary protein connected to the main α1 subunit (the channel-forming protein) of high voltage activated voltage-dependent calcium channels (L-type, N-type, P/Q type, and R-type).[10] Gabapentin is not a direct channel blocker: it exerts its actions by disrupting the regulatory function of α2δ and its interactions with other proteins. Gabapentin prevents delivery of the calcium channels to the cell membrane, reduces the activation of the channels by the α2δ subunit, decreases signaling leading to neurotransmitters release, and disrupts interactions of α2δ with NMDA receptors, neurexins, and thrombospondins.[10][11][12] Out of the four known isoforms of α2δ protein, gabapentin binds with similar high affinity to two: α2δ-1 and α2δ-2.[75] Most of the pharmacological properties of gabapentin are explained by its binding to just one isoform – α2δ-1.[75][11]
The endogenousα-amino acidsL-leucine and L-isoleucine, which resemble gabapentin in chemical structure, bind α2δ with similar affinity to gabapentin and are present in human cerebrospinal fluid at micromolar concentrations.[76] They may be the endogenous ligands of the α2δ subunit, and they competitively antagonize the effects of gabapentin.[76][77] Accordingly, while gabapentin has nanomolar affinity for the α2δ subunit, its potency in vivo is in the low micromolar range, and competition for binding by endogenous L-amino acids is likely to be responsible for this discrepancy.[11]
Gabapentin is a potent activator of voltage-gated potassium channels KCNQ3 and KCNQ5, even at low nanomolar concentrations. However, this activation is unlikely to be the dominant mechanism of gabapentin's therapeutic effects.[78]
The oral bioavailability of gabapentin is approximately 80% at 100 mg administered three times daily once every 8 hours, but decreases to 60% at 300 mg, 47% at 400 mg, 34% at 800 mg, 33% at 1,200 mg, and 27% at 1,600 mg, all with the same dosing schedule.[4][80] Drugs that increase the transit time of gabapentin in the small intestine can increase its oral bioavailability; when gabapentin was co-administered with oral morphine, the oral bioavailability of a 600 mg dose of gabapentin increased by 50%.[80]
Gabapentin at a low dose of 100 mg has a Tmax (time to peak levels) of approximately 1.7 hours, while the Tmax increases to 3 to 4 hours at higher doses.[75] Food does not significantly affect the Tmax of gabapentin and increases the Cmax and area-under-curve levels of gabapentin by approximately 10%.[80]
Gabapentin is eliminatedrenally in the urine.[80] It has a relatively short elimination half-life, with the reported average value of 5 to 7 hours.[80] This value changes with increasing doses, from 5.4 hours for a 200 mg single dose, to 8.3 hours for a 1,400 mg dose.[85] Because of its short elimination half-life, gabapentin must be administered 3 to 4 times per day to maintain therapeutic levels.[86] Gabapentin XR (brand name Gralise) is taken once a day.[87]
Chemistry
Chemical structures of GABA and gabapentin, with commonalities highlighted
Gabapentin is a 3,3-disubstitutedderivative of GABA. Therefore, it is a GABA analogue, as well as a γ-amino acid.[88][89] Specifically, it is a derivative of GABA with a pentyl disubstitution at 3 position, hence, the name - gabapentin, in such a way as to form a six-membered ring. After formation of the ring, the amine and carboxylic groups are not in the same relative positions as they are in the GABA;[90] they are more conformationally constrained.[91]
Synthesis
Synthesis of gabapentin.
A process for chemical synthesis and isolation of gabapentin with high yield and purity[92] starts with conversion of 1,1-cyclohexanediacetic anhydride to 1,1-cyclohexanediacetic acid monoamide, followed by a ‘Hofmann’ rearrangement in an aqueous solution of sodium hypobromite prepared in situ.
History
Gabapentin was designed by researchers at Parke-Davis to be an analogue of the neurotransmitter GABA that could more easily cross the blood–brain barrier and was first described in 1975 by Satzinger and Hartenstein.[90][93] Under the brand name Neurontin, it was first approved in May 1993, for the treatment of epilepsy in the United Kingdom.[94] Approval by the U.S. Food and Drug Administration followed in December 1993, for use as an adjuvant (effective when added to other antiseizure drugs) medication to control partial seizures in adults; that indication was extended to children in 2000.[95][4] Subsequently, gabapentin was approved in the United States for the treatment of postherpetic neuralgia in 2002.[96] A generic version of gabapentin first became available in the United States in 2004.[14] An extended-release formulation of gabapentin for once-daily administration, under the brand name Gralise, was approved in the United States for the treatment postherpetic neuralgia in January 2011.[97][98]
Effective 1 July 2017, Kentucky classified gabapentin as a schedule V controlled substance statewide.[104] Effective 9 January 2019, Michigan also classified gabapentin as a schedule V controlled substance.[105] Gabapentin is scheduled V drug in other states such as West Virginia,[106] Tennessee,[107] Alabama,[108] and Virginia.[109] Gabapentin is not scheduled or considered a controlled substance (as per the Controlled Substances Act) at the federal level.
Off-label promotion
Although some small, non-controlled studies in the 1990s—mostly sponsored by gabapentin's manufacturer—suggested that treatment for bipolar disorder with gabapentin may be promising,[110] the preponderance of evidence suggests that it is not effective.[111]
Subsequent to the corporate acquisition of the original patent holder, the pharmaceutical company Pfizer admitted that there had been violations of FDA guidelines regarding the promotion of unproven off-label uses for gabapentin in the Franklin v. Parke-Davis case (see below).
While off-label prescriptions are common for a number of drugs, marketing of off-label uses of a drug is not.[17] In 2004, Warner-Lambert (which subsequently was acquired by Pfizer) agreed to plead guilty for activities of its Parke-Davis subsidiary, and to pay $430 million in fines to settle civil and criminal charges regarding the marketing of Neurontin for off-label purposes. The 2004 settlement was one of the largest in U.S. history, and the first off-label promotion case brought successfully under the False Claims Act.[112]
Reuters reported on 25 March 2010, that "Pfizer Inc violated federal racketeering law by improperly promoting the epilepsy drug Neurontin ... Under federal RICO law the penalty is automatically tripled, so the finding will cost Pfizer $141 million."[113] The case stems from a claim from Kaiser Foundation Health Plan Inc. that "it was misled into believing Neurontin was effective for off-label treatment of migraines, bipolar disorder and other conditions. Pfizer argued that Kaiser physicians still recommend the drug for those uses",[114] and that "the insurer's website also still lists Neurontin as a drug for neuropathic pain."[115]The Wall Street Journal noted that Pfizer spokesman Christopher Loder said, "We are disappointed with the verdict and will pursue post-trial motions and an appeal."[116] He later added that "the verdict and the judge's rulings are not consistent with the facts and the law."[113]
Gabasync
Gabasync, a treatment consisting of a combination of gabapentin and two other medications (flumazenil and hydroxyzine) as well as therapy, is an ineffective treatment promoted for methamphetamine addiction, though it had also been claimed to be effective for dependence on alcohol or cocaine.[117] It was marketed as PROMETA. While the individual drugs had been approved by the FDA, their off-label use for addiction treatment has not.[118] Gabasync was marketed by Hythiam, Inc. which is owned by Terren Peizer, a former junk bond salesman who has since been indicted for securities fraud relative to another company.[119][120] Hythiam charges up to $15,000 per patient to license its use (of which half goes to the prescribing physician, and half to Hythiam).[121]
In November 2011, the results of a double-blind, placebo-controlled study (financed by Hythiam and carried out at UCLA) were published in the peer-reviewed journal Addiction. It concluded that Gabasync is ineffective: "The PROMETA protocol, consisting of flumazenil, gabapentin and hydroxyzine, appears to be no more effective than placebo in reducing methamphetamine use, retaining patients in treatment or reducing methamphetamine craving."[122]
Barrons, in a November 2005 article entitled "Curb Your Cravings For This Stock", wrote "If the venture works out for patients and the investing public, it'll be a rare success for Peizer, who's promoted a series of disappointing small-cap medical or technology stocks ... since his days at Drexel".[123] Journalist Scott Pelley said to Peizer in 2007: "Depending and who you talk to, you're either a revolutionary or a snake oil salesman."[124][123]60 Minutes, NBC News, and The Dallas Morning News criticized Peizer after the company bypassed clinical studies and government approval when bringing to market Prometa; the addiction drug proved to be completely ineffective.[125][126][117][127] Journalist Adam Feuerstein opined: "most of what Peizer says is dubious-sounding hype".[128]
Brand names
Gabapentin was originally marketed under the brand name Neurontin. Since it became generic, it has been marketed worldwide using over 300 different brand names.[1] An extended-release formulation of gabapentin for once-daily administration was introduced in 2011, for postherpetic neuralgia under the brand name Gralise.[129]
Gabapentin when taken in excess, can induce euphoria, a sense of calm, a marijuana-like high, improved sociability, and reduced alcohol or cocaine cravings.[133][134][135] Also known on the streets as "Gabbies",[136] gabapentin is increasingly abused and misused for these euphoric effects.[137][138] About 1 percent of the responders to an Internet poll and 22 percent of those attending addiction facilities had a history of abuse of gabapentin.[70][139] Gabapentin misuse, toxicity, and use in suicide attempts among adults in the US increased from 2013 to 2017.[140]
After Kentucky's implementation of stricter legislation regarding opioid prescriptions in 2012, there was an increase in gabapentin-only and multi-drug use in 2012–2015. The majority of these cases were from overdose in suspected suicide attempts. These rates were also accompanied by increases in abuse and recreational use.[141]
Withdrawal symptoms, often resembling those of benzodiazepine withdrawal, play a role in the physical dependence some users experience.[71] Its misuse predominantly coincides with the usage of other CNS depressant drugs, namely opioids, benzodiazepines, and alcohol.[142]
Veterinary use
In cats, gabapentin can be used as an analgesic in multi-modal pain management,[143] anxiety medication to reduce stress in cats for travel or vet visits,[144] and anticonvulsant.[145] Veterinarians may prescribe gabapentin as an anticonvulsant and pain reliever in dogs. It is also used to treat chronic pain-associated nerve inflammation in horses and dogs. Side effects include tiredness and loss of coordination but they generally go away within 24 hours.[146][145]
^ abcdeGoa KL, Sorkin EM (September 1993). "Gabapentin. A review of its pharmacological properties and clinical potential in epilepsy". Drugs. 46 (3): 409–427. doi:10.2165/00003495-199346030-00007. PMID7693432.
^ abcdStahl SM, Porreca F, Taylor CP, Cheung R, Thorpe AJ, Clair A (June 2013). "The diverse therapeutic actions of pregabalin: is a single mechanism responsible for several pharmacological activities?". Trends in Pharmacological Sciences. 34 (6): 332–339. doi:10.1016/j.tips.2013.04.001. PMID23642658.
^ abcMula M, Pini S, Cassano GB (June 2007). "The role of anticonvulsant drugs in anxiety disorders: a critical review of the evidence". Journal of Clinical Psychopharmacology. 27 (3): 263–272. doi:10.1097/jcp.0b013e318059361a. PMID17502773. S2CID38188832.
^Muncie HL, Yasinian Y, Oge' L (November 2013). "Outpatient management of alcohol withdrawal syndrome". American Family Physician. 88 (9): 589–595. PMID24364635.
^Ahmed S, Stanciu CN, Kotapati PV, Ahmed R, Bhivandkar S, Khan AM, et al. (August 2019). "Effectiveness of Gabapentin in Reducing Cravings and Withdrawal in Alcohol Use Disorder: A Meta-Analytic Review". The Primary Care Companion for CNS Disorders. 21 (4). doi:10.4088/PCC.19r02465. PMID31461226. S2CID201662179.
^Shan D, Zou L, Liu X, Shen Y, Cai Y, Zhang J (June 2020). "Efficacy and safety of gabapentin and pregabalin in patients with vasomotor symptoms: a systematic review and meta-analysis". American Journal of Obstetrics and Gynecology. 222 (6): 564–579.e12. doi:10.1016/j.ajog.2019.12.011. PMID31870736. S2CID209462426.
^Winkelmann J, Allen RP, Högl B, Inoue Y, Oertel W, Salminen AV, et al. (July 2018). "Treatment of restless legs syndrome: Evidence-based review and implications for clinical practice (Revised 2017)§". Movement Disorders. 33 (7): 1077–1091. doi:10.1002/mds.27260. PMID29756335. S2CID21669996.
^Aazh H, El Refaie A, Humphriss R (December 2011). "Gabapentin for tinnitus: a systematic review". American Journal of Audiology. 20 (2): 151–158. doi:10.1044/1059-0889(2011/10-0041). PMID21940981.
^Kim JB, Jung JM, Park MH, Lee EJ, Kwon DY (November 2017). "Negative myoclonus induced by gabapentin and pregabalin: A case series and systematic literature review". Journal of the Neurological Sciences. 382: 36–39. doi:10.1016/j.jns.2017.09.019. PMID29111014. S2CID32010921.
^Desai A, Kherallah Y, Szabo C, Marawar R (March 2019). "Gabapentin or pregabalin induced myoclonus: A case series and literature review". Journal of Clinical Neuroscience. 61: 225–234. doi:10.1016/j.jocn.2018.09.019. PMID30381161. S2CID53165515.
^Leith WM, Lambert WE, Boehnlein JK, Freeman MD (January 2019). "The association between gabapentin and suicidality in bipolar patients". International Clinical Psychopharmacology. 34 (1): 27–32. doi:10.1097/YIC.0000000000000242. PMID30383553. S2CID54130760.
^R.C. Baselt, Disposition of Toxic Drugs and Chemicals in Man, 8th edition, Biomedical Publications, Foster City, CA, 2008, pp. 677–8. ISBN978-0-9626523-7-0.
^ abcdeSills GJ (February 2006). "The mechanisms of action of gabapentin and pregabalin". Current Opinion in Pharmacology. 6 (1): 108–113. doi:10.1016/j.coph.2005.11.003. PMID16376147.
^ abcdefCalandre EP, Rico-Villademoros F, Slim M (November 2016). "Alpha2delta ligands, gabapentin, pregabalin and mirogabalin: a review of their clinical pharmacology and therapeutic use". Expert Review of Neurotherapeutics. 16 (11): 1263–1277. doi:10.1080/14737175.2016.1202764. PMID27345098. S2CID33200190.
^ abDooley DJ, Taylor CP, Donevan S, Feltner D (February 2007). "Ca2+ channel alpha2delta ligands: novel modulators of neurotransmission". Trends in Pharmacological Sciences. 28 (2): 75–82. doi:10.1016/j.tips.2006.12.006. PMID17222465.
^Davies A, Hendrich J, Van Minh AT, Wratten J, Douglas L, Dolphin AC (May 2007). "Functional biology of the alpha(2)delta subunits of voltage-gated calcium channels". Trends in Pharmacological Sciences. 28 (5): 220–228. doi:10.1016/j.tips.2007.03.005. PMID17403543.
^del Amo EM, Urtti A, Yliperttula M (October 2008). "Pharmacokinetic role of L-type amino acid transporters LAT1 and LAT2". European Journal of Pharmaceutical Sciences. 35 (3): 161–174. doi:10.1016/j.ejps.2008.06.015. PMID18656534.
^ abcdefghiBockbrader HN, Wesche D, Miller R, Chapel S, Janiczek N, Burger P (October 2010). "A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin". Clinical Pharmacokinetics. 49 (10): 661–669. doi:10.2165/11536200-000000000-00000. PMID20818832. S2CID16398062.
^ abcdDickens D, Webb SD, Antonyuk S, Giannoudis A, Owen A, Rädisch S, et al. (June 2013). "Transport of gabapentin by LAT1 (SLC7A5)". Biochemical Pharmacology. 85 (11): 1672–1683. doi:10.1016/j.bcp.2013.03.022. PMID23567998.
^ abMüller CE (November 2009). "Prodrug approaches for enhancing the bioavailability of drugs with low solubility". Chemistry & Biodiversity. 6 (11): 2071–2083. doi:10.1002/cbdv.200900114. PMID19937841. S2CID32513471.
^Baillie JK, Power I (January 2006). "The mechanism of action of gabapentin in neuropathic pain". Current Opinion in Investigational Drugs. 7 (1): 33–39. PMID16425669.
^Kjellsson MC, Ouellet D, Corrigan B, Karlsson MO (October 2011). "Modeling sleep data for a new drug in development using markov mixed-effects models". Pharmaceutical Research. 28 (10): 2610–2627. doi:10.1007/s11095-011-0490-x. PMID21681607. S2CID22241527.
^Martinez GM, Olabisi J, Ruekert L, Hasan S (July 2019). "A Call for Caution in Prescribing Gabapentin to Individuals With Concurrent Polysubstance Abuse: A Case Report". Journal of Psychiatric Practice. 25 (4): 308–312. doi:10.1097/PRA.0000000000000403. PMID31291212. S2CID195878855.
^Trestman RL, Appelbaum KL, Metzner JL (April 2015). Oxford Textbook of Correctional Psychiatry. Oxford University Press. p. 167. ISBN978-0199360574.
^Bonnet U, Scherbaum N (February 2018). "[On the risk of dependence on gabapentinoids]". Fortschritte der Neurologie-Psychiatrie (in German). 86 (2): 82–105. doi:10.1055/s-0043-122392. PMID29179227.
^Faryar KA, Webb AN, Bhandari B, Price TG, Bosse GM (June 2019). "Trending gabapentin exposures in Kentucky after legislation requiring use of the state prescription drug monitoring program for all opioid prescriptions". Clinical Toxicology. 57 (6): 398–403. doi:10.1080/15563650.2018.1538518. PMID30676102. S2CID59226292.
^Vettorato E, Corletto F (September 2011). "Gabapentin as part of multi-modal analgesia in two cats suffering multiple injuries". Veterinary Anaesthesia and Analgesia. 38 (5): 518–520. doi:10.1111/j.1467-2995.2011.00638.x. PMID21831060.
^van Haaften KA, Forsythe LR, Stelow EA, Bain MJ (November 2017). "Effects of a single preappointment dose of gabapentin on signs of stress in cats during transportation and veterinary examination". Journal of the American Veterinary Medical Association. 251 (10): 1175–1181. doi:10.2460/javma.251.10.1175. PMID29099247. S2CID7780988.
^ ab"Gabapentin". Plumb's Veterinary Drugs. Retrieved 2 April 2021.